Navigation Links
AlphaRx Presents Company Overview and New Product Candidates at the Rodman Renshaw Healthcare Conference
Date:9/14/2009

MARKHAM, ON, Sept. 14 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB: ALRX). Speaking at the 11th Annual Rodman Renshaw Healthcare Conference in New York City, AlphaRx Director Dr. David Milroy presented a company overview focusing on the Company's product pipeline, nano drug delivery platform and the significant developments anticipated within the next 12 months. In Summary, AlphaRx will have 3-4 products in different stages of clinical development by the end of 2010, which have major market indications and opportunities, producing a portfolio of short to long term drug candidates to position the company for stable and sustainable growth. In addition, AlphaRx presented 2 new product candidates ARX1088 and ARX2038 which are being developed for herpes and lipid management respectively. These products have excellent safety profile and have over 25 years of successful clinical applications outside the US. AlphaRx is developing a new dosage form for ARX1088 and ARX2038 and planning to initiate Phase II clinical trails in the later part of 2010.

About ARX1088

The active ingredient in ARX1088 is an orally active interferon inducer. It primarily acts as an inducer of type I, alpha or beta interferon. In humans, these interferon levels double as early as four hours after administration of the drug. After 12-24 hours the levels can be one hundred or even several thousand fold higher, with maximum level achieved at 48 hours. It is a drug that is currently approved to treat certain anti-viral indications outside USA. ARX1088 is being developed as a topical treatment for herpes Simplex 1 and 2, as the mechanism of action is not directed at killing the virus, but through boosting the host's own immune system.

About ARX2038

The active ingredient in ARX2038 is a synthetic compound with a combination of unique properties. It demonstrates, heart, neuroprotective and cholesterol lowering properties.

It has extremely low toxicity (no signs of toxicity at 10,000 mg/kg) and produces no teratogenic, mutagenic or carcinogenic effects. Allergic reactions are extremely rare.

This compound significantly decreases cholesterol levels by up to 36%, LDL by 20%, triglycerides by 13% and elevates HDL by 47%. ARX2038 is a unique extended release formulation of this compound.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ALPHARx to Present at Rodman Renshaw Annual Global Investment Conference
2. AlphaRx Concludes GAI-122 Formulation Development Intended For The Prevention of Delirium
3. AlphaRx Receives China Patent on Its Drug Delivery Platform
4. AlphaRx and Venturepharm Announce Collaboration Agreement
5. AlphaRx Presents Positive Preclinical Data on Zysolin(TM) Inhalable Nanoparticles at Controlled Release Society Annual Meeting
6. AlphaRx Unveils its China Strategy
7. AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
8. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
9. AlphaRx Shareholder Update
10. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
11. AlphaRx Signs Cooperative Research and Development Agreement with US Army
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... ... at Zuckerberg San Francisco General Hospital on April 5-7. The series is a ... create new habits. The workshops cover a broad range of topics, including coaching ...
(Date:2/12/2016)... ... ... Every winter, someone is killed, injured or loses a home in an accident ... of the Allegheny Health Network, has partnered with Etna Volunteer Fire Department, and Monroeville ... , “Space Heaters Need Space” aims to bring awareness to the risks ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a ... initiating a charity drive that will raise funds earmarked to purchase computers and software ... Elementary School. , “My school is in a low-income area and has more than ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one of ... of physicians establishing, leading and partnering with ambulatory surgery centers across the United States. ... also known as an ASC, is a modern health care facility focused on providing ...
(Date:2/12/2016)... ... 12, 2016 , ... Young Asset Protection, a full service ... the latest charity campaign in their community enrichment program. Art Expression utilizes after-school ... cause are currently being accepted at: http://artexpressioninc.org/ . , Art Expression is ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... LONDON , Feb. 11, 2016 The ... current and future adoption patterns on the usage of ... include the following: - Timeframe of liquid ... types—CTCs, ctDNA, cfDNA and Evs—by organization type - Sample ... sample types: blood, saliva, stool, serum, and so on. ...
(Date:2/11/2016)... , Feb. 11, 2016 ... commonly used in laboratories. These may range from microscope ... Laboratory glassware is made from borosilicate glass because of ... plasticware, on the other hand, started gaining popularity over ... was easier to replace glass with plastic in several ...
(Date:2/11/2016)... DUNKIRK, N.Y. , Feb. 11, 2016  Governor ... Athenex that will create 1,400 jobs throughout ... by a partnership with the SUNY Polytechnic Institute, includes ... the Conventus Building in Buffalo , ... square foot manufacturing facility in Dunkirk ...
Breaking Medicine Technology: